Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar’s Bidose Liquid System (BDS) for Seelos’ SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the treatment of suicidal ideation in patients with major depressive disorder. The company noted that the agreement also includes the rights to use the device for other indications not disclosed at this time.
Seelos was granted Fast Track designation for SLS-002 for the treatment of suicidality in 2019. In February 2021, the company announced that it had repurchased royalties on any future sales of SLS-002.
Seelos Chairman and CEO Raj Mehra commented, “Aptar is a world-class organization and has been an integral partner for our intranasal ketamine program since our inception. This partnership strengthens the collaboration between Seelos and Aptar, and further protects the SLS-002 franchise.”
The company says that Part 1 of the ongoing Phase 2 study was completed on March 30 2021 and that it expects to release data in the second quarter of 2021. The second part of the study, which will be a registration trial, is expected to enroll 120 patients.
Read the Seelos Therapeutics press release.
